Skip to main content

Aardvark Therapeutics, Inc.

AARD
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001774857

In the last 90 days, Aardvark Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 71 institutions reported holding it in 13F filings for Q2 2026, worth $54.3M in total; no superinvestor holds it.

Q1 2025 vs. Q4 2024

How the institutions holding Aardvark Therapeutics, Inc. changed between Q4 2024 and Q1 2025.

All holders in Q1 2025All holders in Q4 2024

13F holders of AARD: Q4 2024 compared with Q1 2025
MeasureQ4 2024Q1 2025Change
Holders027+27
Shares08.69M+8.69M
Value$0$65.1M+$65.1M

New holders (27)

Institutions that held Aardvark Therapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.

Institutions new to AARD in Q1 2025
InstitutionSharesValue% of portfolio
Decheng Capital LLC3,917,299$29.4M8.25%
Citadel Advisors LLC1,274,084$9.44M0.01%
Laurion Capital Management LP808,243$6.07M0.47%
Cormorant Asset Management, LP800,189$6.01M0.45%
Braidwell LP500,000$3.75M0.13%
Suvretta Capital Management, LLC312,500$2.35M0.09%
Adage Capital Partners GP, L.L.C.250,000$1.88M0.00%
Vanguard Group Inc165,491$1.24M0.00%
Schonfeld Strategic Advisors LLC143,951$1.08M0.01%
Silverarc Capital Management, LLC119,496$897.4K0.19%
Cantor Fitzgerald, L. P.66,682$500.8K0.02%
Millennium Management LLC65,640$493.0K0.00%
Geode Capital Management, LLC59,600$447.6K0.00%
Balyasny Asset Management LLC35,435$266.1K0.00%
BNP Paribas Arbitrage, SA34,690$260.5K0.00%
Goldman Sachs Group Inc20,311$152.5K0.00%
BlackRock, Inc.18,776$141.0K0.00%
Two Sigma Investments, LP15,424$115.8K0.00%
UBS Group AG14,705$110.4K0.00%
Squarepoint Ops LLC14,186$106.5K0.00%
Northern Trust Corp14,001$105.1K0.00%
Point72 (DIFC) Ltd12,797$96.1K0.01%
Walleye Capital LLC11,730$88.1K0.00%
Bank of America Corp4,620$34.7K0.00%
JPMorgan Chase & Co3,100$23.3K0.00%
Morgan Stanley2,218$16.7K0.00%
Point72 Asia (Singapore) Pte. Ltd.1,284$9.64K0.00%

Sold out (0)

Institutions that held Aardvark Therapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.

None.